
    
      Coldplay III is a multi-center, prospective study that will provide evidence of the efficacy
      and safety of the System in treatment of patients with previously untreated (treatment na√Øve)
      low grade dysplasia (LGD) or high grade dysplasia (HGD) BE. Subjects may have a maximum of
      five (5) ablation treatment sessions during their 12 months of study participation to achieve
      complete eradication of their dysplastic BE and intestinal metaplasia. As many ablations as
      needed to treat the dysplastic areas are allowed in each treatment session at the discretion
      of the investigator.
    
  